Form 4: Arbutus Biopharma Director Keith S. Manchester Granted Stock Options

Director Keith S. Manchester of Arbutus Biopharma Corp. was granted stock options for 67,000 common shares on May 23, 2024, fully vested and exercisable immediately.

Summary

• On May 23, 2024, Keith S. Manchester, a director of Arbutus Biopharma Corp., was granted stock options.
• The options allow Manchester to purchase 67,000 common shares of Arbutus Biopharma.
• The exercise price for the options is $3.28 per share, reflecting the closing price of the company's common shares on the Nasdaq Stock Market on the grant date.
• The options are fully vested and exercisable as of the grant date.
• The options expire on May 23, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine grant of stock options, which is neither particularly positive nor negative on its own. It's a standard practice for director compensation.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• Immediate vesting suggests confidence in the director's continued contributions to the company.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

Stock option grants are a common practice in the biopharmaceutical industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company. This is a standard method of compensation for directors.

Comparison to Industry Standards

• Stock option grants to directors are a common practice across the biopharmaceutical industry.
• Companies like Gilead Sciences, Amgen, and Vertex Pharmaceuticals also utilize stock options as part of their compensation packages for board members.
• The size of the grant (67,000 shares) would need to be compared to the overall compensation structure and market capitalization of Arbutus Biopharma to determine if it is in line with industry standards.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders' equity if the options are exercised.
• The grant incentivizes the director to work towards increasing shareholder value.

Key Dates